<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755520</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. D00112</org_study_id>
    <secondary_id>2012-003630-16</secondary_id>
    <nct_id>NCT01755520</nct_id>
  </id_info>
  <brief_title>Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG</brief_title>
  <acronym>TiCAB</acronym>
  <official_title>A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study ist to test the hypothesis that ticagrelor is superior to
      Aspirin (ASA) fort he prevention of major cardio- and cerebrovascular events (MACCE) in
      patients undergoing artery bypass operation.

      The primary efficiacy MACCE-endpoint is the composite of cardiovascular death, myocardial
      infarction, recurent revascularisation, and stroke at twelve month after coronary artery
      bypass operation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For stable patients who underwent coronary bypass operation, Aspirin alone currently
      represents the gold standard of antiplatelet treatment.

      The CABG substudy of the PLATO-trial (http://www.nejm.org/doi/full/10.1056/NEJMoa0904327)
      comprising more than 1200 patients has convincingly shown a high significant reduction of
      cardiovascular and all-cause mortality for patients recieving Aspirin and Ticagrelor as
      compared to those subjects randomized to Aspirin plus Clopidogrel. Moreover the results of
      the PLATO CABG substudy showed that benefits of Ticagrelor increase with decreasing Aspirin
      doses. Therefore Ticagrelor monotherapy (2x 90mg/day) appears to offer the best balance of
      safety with anticipated improved efficacy over Aspirin (1x 100mg/day) alone, but until now
      there are no further data available to support this hypothesis.

      Hence this study (TiCAB) is assigned as a pivotal efficacy and safety study of Ticagrelor in
      patients undergoing coronary artery bypass operation and to test the hypothesis that
      ticagrelor is superior to Aspirin for the prevention of major cardio- and cerebrovascular
      events (MACCE) in this patient population.

      The TiCAB trial is designed as a randomized, double-blind, double-dummy, parallel group,
      phase III, multicenter study, comparing the efficacy and safety of Ticagrelor 90mg
      administered twice daily with Aspirin 100mg once daily, for the prevention of MACCE within
      the first year after CABG operation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMB Interim Analyses
  </why_stopped>
  <start_date>April 24, 2013</start_date>
  <completion_date type="Actual">May 19, 2018</completion_date>
  <primary_completion_date type="Actual">May 19, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
    <description>Composite of cardiovascular death, myocardial infarction, target vessel revascularization, and stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding events</measure>
    <time_frame>within 12 months after coronary arerty bypass surgery</time_frame>
    <description>Incidence of major bleeding events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
    <description>All cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>at 12 months after coronary artery bypass surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1893</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Stable Angina</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: Ticagrelor verum + Aspirin placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: Aspirin verum + Ticagrelor placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>90mg twice daily dose</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 100mg once daily</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>ASS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Ticagrelor</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Aspirin</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years of age or older

          2. Informed, written consent by the patient

          3. Indication for CABG surgery:

               -  coronary three vessel disease, or

               -  left main stenosis, or

               -  two vessel disease with impaired left ventricular function (&lt;50%)

        Exclusion Criteria:

          1. Cardiogenic shock, haemodynamic instability

          2. Indication for oral anticoagulation or dual antiplatelet therapy that can not be
             stopped after CABG

          3. Need for concomitant non-coronary surgery (e.g. valve replacement)

          4. Intolerance of or Allergy to Ticagrelor or ASA or any of their ingredients

          5. History of bleeding diathesis within three months prior presentation

          6. History of significant gastrointestinal bleeding within six months prior presentation

          7. History of intracranial hemorrhage

          8. History of moderate to severe liver impairment (Child Pugh B or C)

          9. Chronic renal insufficiency requiring dialysis

         10. Patient with an increased risk of bradycardic events (e.g. patients without a
             pacemaker who have sick sinus syndrome, 2nd or 3rd degree AV block or
             bradycardic-related syncope)

         11. Known, clinically important thrombocytopenia (i.e. &lt;100.000/µl)

         12. Known, clinically important anaemia (i.e. &lt;10mg/dl)

         13. Participation in another investigational drug or device study in the last 30 days

         14. Pregnancy or lactation (for premenopausal women 2 methods of reliable contraception,
             one of which must be barrier method, are required); in women with childbearing
             potential a pregnancy test is mandatory

         15. Concomitant oral or intravenous therapy (see examples below) with strong CYP3A
             inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers
             which cannot be stopped for the course of the study

               -  Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin,
                  clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir,
                  atazanavir, over 1 litre daily of grapefruit juice.

               -  Substrates with narrow therapeutic index: cyclosporine, quinidine.

               -  Strong inducers: rifampin/rifampicin, phenytoin, carbamazepine.

         16. Life expectancy less than 12 months that may result in protocol non-compliance or a
             risk for being lost to follow-up, active cancer

         17. Indication for major surgery (e.g. cancer treatment, carotid surgery, cerebral
             surgery, major vascular surgery)

         18. Previous enrollment or randomization of treatment in the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heribert Schunkert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Munich Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Brandenburg in Bernau</name>
      <address>
        <city>Bernau bei Berlin</city>
        <state>Brandenburg</state>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Kreislaufzentrum Rothenburg an der Fulda</name>
      <address>
        <city>Rotenburg An Der Fulda</city>
        <state>Hesse</state>
        <zip>36199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäßzentrum</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheit Nord gGmbH, Klinikum Links der Weser gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Herzzentrum Cottbus GmbH</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg / Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St.Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Süd</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schweizer Herz- und Gefässchirurgie</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CABG</keyword>
  <keyword>CAD</keyword>
  <keyword>antiplatelet drug</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

